PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Rapid Turnaround Time and Improved Patient Outcomes Set European POCT Market on Path of Exponential Growth States Frost & Sullivan - Advances in analytical technology and healthcare services have led to the significant development of, and demand for, point of care testing (POCT)
Rapid Turnaround Time and Improved Patient Outcomes Set European POCT Market on Path of Exponential Growth States Frost & Sullivan

 

NewswireToday - /newswire/ - London, United Kingdom, 2011/01/12 - Advances in analytical technology and healthcare services have led to the significant development of, and demand for, point of care testing (POCT).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Some POCT devices have been used in the hospital environment, general practitioner (GP) surgeries and even in home settings (for example, urine and glucose dipsticks and meters) for many years. More recently, the range of analysers and tests available has expanded considerably, and the technology has become easier to use and more robust.

New analysis from Frost & Sullivan (drugdiscovery.frost.com), European Point of Care Testing Market, finds that the market was worth $1.30 billion in 2009 and estimates this to reach $2.70 billion in 2016. The research covers the POCT market in Western Europe pertaining to bench-top and handheld analysers that are currently in use for point of care testing in clinical settings. The key segments that are considered include cardiac, diabetes, infectious diseases, blood gas and electrolytes, fertility, coagulation and haematology.

It is now possible to provide a rapid test result in a timely manner in the immediate vicinity of the patient such as in the Emergency Department (ED) or the Intensive Care Unit (ICU). The rapidity of obtaining a result can increase clinical effectiveness and contribute to improved outcomes for patients. However, it is imperative that the result provided by the device is accurate and reliable. The improved reliability and range of POCT devices are resulting in their increasing use in community clinics, GP surgeries and the home environment.

"The most significant advantage of POCT is the fact that it produces results within a short duration ranging from seconds to minutes," notes Frost & Sullivan Senior Research Analyst Rasika Ramachandran. "This is important in some critical situations such as in the emergency department when the patient is in a critical state."

Rapid return of results aids the clinician in making crucial treatment decisions on the spot. In contrast, conventional lab testing often takes a long time and can delay the treatment of a patient, causing unnecessary expenditures in terms of hospital stays and avoidable agony to the patient.

"POCT eliminates the need to transport a specimen to a remote laboratory and prevents errors related to transfer of data and transcription," states Ramachandran. "These tests enable the provision of emergency results and simplify the logistics of frequent monitoring."

Hand-held systems can undertake a single assay or a panel of simultaneous tests to offer better-quality patient care, better operational efficiency and increased cost-effectiveness.

The European point of care market is currently growing at double-digit growth rates, which is significant especially as it comes from an already high base. This growth rate is projected to increase as more European governments widen adoption of POCT, making it more mainstream.

The implementation and management of programmes for POCT can be difficult because these require input and coordination with many different healthcare professionals. Additionally, POCT must compete with established testing methods and resource availability, as resources are already allocated to labs.

"In the hospital environment, the development and use of POC programmes can require input from various stakeholders such as primary caregivers, POC managers, clinical laboratory personnel and, sometimes, the hospital administration as well," explains Ramachandran. "Therefore, the appropriate stakeholders need to be convinced of the value of integrating POCT methods over established programmes."

This is expected to be a key challenge in this market until POCT programmes are streamlined to work seamlessly with existing testing methods and protocols. All the stakeholders will need to make a concerted effort to implement a POCT programme. This trend will gain more momentum as the benefits of this testing modality become progressively more apparent.

The UK Government is making significant progress in streamlining the process of implementing POCT programmes. It will not be long before other European governments take their cue and attempt to emulate this pioneering effort.

If you are interested in more information on Frost & Sullivan's latest research on the European Point of Care Testing Market, please send an email to Katja Feick, Corporate Communications, at katja.feick[.]frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

European Point of Care Testing Market is part of the Drug Discovery Technologies Growth Partnership Services programme, which also includes research on the following markets: European Tissue Diagnostics Markets and European Diabetes Diagnostics Market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.

European Point of Care Testing Market / M59F

twitter.com/frost_sullivan | facebook.com/FrostandSullivan

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Rapid Turnaround Time and Improved Patient Outcomes Set European POCT Market on Path of Exponential Growth States Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Katja Feick 
+49 (0) 69 7703343 katja.feick[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)